Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science
View original at finance.yahoo.comAbcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through open science, a new public-…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Abcam serves 750,000 researchers in over 130 countries to help them reach results faster in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders
80% confidenceLIGAND-AI aims to change drug discovery by combining advanced laboratory technologies with computational methods to create a seamless pipeline from experiment to prediction, generating billions of data points
80% confidenceThe project brings together scientists and companies from across disciplines within an open science ecosystem, with diverse scientific communities coalescing around a common vision to generate and share valuable chemical data openly with the world
80% confidenceLIGAND-AI represents the next frontier in drug discovery, combining cutting-edge AI with large-scale experimental science to build predictive models that will unlock thousands of new targets
80% confidenceThe project represents a major step toward the mission of Target 2035 to discover chemical modulators for every human protein by the year 2035
80% confidence
